Arrowhead Pharmaceuticals (ARWR)
Develops targeted RNAi medicines and markets REDEMPLO for familial chylomicronemia syndrome.
$71.86
After hours+0.03 (+0.04%)
At close$71.83(+4.42%)
Something off on this page? Send us feedback.
Next report
Nov 24, 26
in 63 days
EPS estimate
−$1.59
Revenue estimate
$59.4M
Fiscal quarter
Q4 FY26
EPSReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$1.39$2.75−$1.26−$0.18$0.22−$0.93−$1.36Pending
Estimate−$0.42−$0.06−$0.94−$0.11$0.60−$1.09−$1.28−$1.59
Surprise−231.0%+4,683.3%−34.0%−61.3%−63.3%+14.7%−6.3%—
RevenueReportedEstimate
Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$2.5M$542.7M$27.8M$256.5M$264.0M$73.7M$75.3MPending
Estimate$19.1M$116.3M$154.1M$175.3M$213.9M$73.8M$44.2M$59.4M
Surprise−86.9%+366.8%−82.0%+46.3%+23.4%−0.1%+70.4%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Sep 2027 | −$0.83 | — | — |
| Jun 2027 | −$1.39 | — | — |
| Mar 2027 | −$1.46 | — | — |
| Dec 2026 | −$1.35 | — | — |
| Nov 2026 | −$1.59 | — | — |
| Aug 2026 | −$1.28 | −$1.36 | −6.3% |
| May 2026 | −$1.09 | −$0.93 | +14.7% |
| Feb 2026 | $0.60 | $0.22 | −63.3% |
| Nov 2025 | −$0.11 | −$0.18 | −61.3% |
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Dec 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Feb 2018 | |||
| Dec 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Feb 2017 | |||
| Dec 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Feb 2016 | |||
| Dec 2015 | |||
| Aug 2015 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Sep 2027 | −$0.83 | — | — | $144.1M | — | — | — |
| Jun 2027 | −$1.39 | — | — | $45.3M | — | — | — |
| Mar 2027 | −$1.46 | — | — | $31.2M | — | — | — |
| Dec 2026 | −$1.35 | — | — | $42.6M | — | — | — |
| Nov 24, 2026 | −$1.59 | — | — | $59.4M | — | — | — |
| Aug 4, 2026 | −$1.28 | −$1.36 | −6.3% | $44.2M | $75.3M | +70.4% | −3.0% |
| May 7, 2026 | −$1.09 | −$0.93 | +14.7% | $73.8M | $73.7M | −0.1% | −6.8% |
| Feb 5, 2026 | $0.60 | $0.22 | −63.3% | $213.9M | $264.0M | +23.4% | −0.2% |
| Nov 25, 2025 | −$0.11 | −$0.18 | −61.3% | $175.3M | $256.5M | +46.3% | +23.3% |
| Aug 7, 2025 | |||||||
| May 12, 2025 | |||||||
| Feb 10, 2025 | |||||||
| Nov 26, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 9, 2024 | |||||||
| Feb 6, 2024 | |||||||
| Nov 29, 2023 | |||||||
| Aug 7, 2023 | |||||||
| May 2, 2023 | |||||||
| Feb 6, 2023 | |||||||
| Nov 28, 2022 | |||||||
| Aug 4, 2022 | |||||||
| May 10, 2022 | |||||||
| Feb 2, 2022 | |||||||
| Nov 22, 2021 | |||||||
| Aug 5, 2021 | |||||||
| May 4, 2021 | |||||||
| Feb 4, 2021 | |||||||
| Nov 23, 2020 | |||||||
| Aug 5, 2020 | |||||||
| May 7, 2020 | |||||||
| Feb 5, 2020 | |||||||
| Nov 25, 2019 | |||||||
| Aug 5, 2019 | |||||||
| May 8, 2019 | |||||||
| Feb 7, 2019 | |||||||
| Dec 11, 2018 | |||||||
| Aug 7, 2018 | |||||||
| May 8, 2018 | |||||||
| Feb 9, 2018 | |||||||
| Dec 12, 2017 | |||||||
| Aug 3, 2017 | |||||||
| May 3, 2017 | |||||||
| Feb 6, 2017 | |||||||
| Dec 14, 2016 | |||||||
| Aug 9, 2016 | |||||||
| May 10, 2016 | |||||||
| Feb 9, 2016 | |||||||
| Dec 14, 2015 | |||||||
| Aug 4, 2015 |